---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-249011"
form_type: "8-K"
ticker: "FULC"
cik: "0001680581"
company_name: "Fulcrum Therapeutics, Inc."
filed_at: "2023-10-02T23:59:59+00:00"
generated_at: "2026-06-10T06:23:29.053246+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.4
calibrated_materiality_score: 0.4
confidence: "high"
source: SEC EDGAR
---

# Fulcrum Therapeutics eliminates COO role; Mel Hayes transitions to EVP, Patient Experience

## Summary
- COO position eliminated effective Oct 2, 2023; no principal operating officer thereafter.
- Mel Hayes remains as Executive Vice President, Patient Experience under amended agreement.
- New role has 12-month term; compensation and severance unchanged.
- Restructuring aimed at streamlining company functions.

## SEC filing metadata
- accession: 0001193125-23-249011
- form_type: 8-K
- ticker: FULC
- cik: 0001680581
- company_name: Fulcrum Therapeutics, Inc.
- filed_at: 2023-10-02T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.4
- calibrated_materiality_score: 0.4
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1680581/000119312523249011/0001193125-23-249011-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1680581/000119312523249011/d495158d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-249011
- JSON: https://secwatch.observer/filing/0001193125-23-249011.json
- Plain text: https://secwatch.observer/filing/0001193125-23-249011.txt

## Key facts
- Executive change
  Mel Hayes changed role as Executive Vice President, Patient Experience at Fulcrum Therapeutics, Inc..
  - Role: Executive Vice President, Patient Experience
  source text: On September 28, 2023, in connection with a decision to streamline certain functions within the company, Fulcrum Therapeutics, Inc., or Fulcrum, notified Mel Hayes, Fulcrum’s current chief operating officer (and principal operating officer) that it was eliminating his position effective October 2, 2023, following which, Fulcrum does not have a principal operating officer. Mr. Hayes agreed to remain with Fulcrum as its Executive Vice President, Patient Experience, and in connection therewith, entered into an amended and restated employment agreement reflecting his new role and title at Fulcrum.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1680581/000119312523249011/0001193125-23-249011-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.